Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01137812
Registration number
NCT01137812
Ethics application status
Date submitted
3/06/2010
Date registered
4/06/2010
Date last updated
15/01/2015
Titles & IDs
Public title
The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)
Query!
Scientific title
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Versus Sitagliptin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy
Query!
Secondary ID [1]
0
0
28431754DIA3015
Query!
Secondary ID [2]
0
0
CR017185
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 2
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Sitagliptin 100 mg
Treatment: Drugs - Canagliflozin 300 mg
Treatment: Drugs - Metformin
Treatment: Drugs - Sulphonylurea
Experimental: Canagliflozin 300 mg - Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
Active comparator: Sitagliptin 100 mg - Each patient will receive 100 mg of sitagliptin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
Treatment: Drugs: Sitagliptin 100 mg
One 100 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
Treatment: Drugs: Canagliflozin 300 mg
One 300 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
Treatment: Drugs: Metformin
Patients will continue to take background therapy with Metformin for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
Treatment: Drugs: Sulphonylurea
Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change in HbA1c From Baseline to Week 52
Query!
Assessment method [1]
0
0
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change.
Query!
Timepoint [1]
0
0
Day 1 (Baseline) and Week 52
Query!
Secondary outcome [1]
0
0
Percentage of Patients With HbA1c <7% at Week 52
Query!
Assessment method [1]
0
0
The table below shows the percentage of patients with HbA1c \<7% at Week 52 in each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the percentage.
Query!
Timepoint [1]
0
0
Week 52
Query!
Secondary outcome [2]
0
0
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 52
Query!
Assessment method [2]
0
0
The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change.
Query!
Timepoint [2]
0
0
Day 1 (Baseline) and Week 52
Query!
Secondary outcome [3]
0
0
Percent Change in Body Weight From Baseline to Week 52
Query!
Assessment method [3]
0
0
The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean percent change.
Query!
Timepoint [3]
0
0
Day 1 (Baseline) and Week 52
Query!
Secondary outcome [4]
0
0
Change in Systolic Blood Pressure (SBP) From Baseline to Week 52
Query!
Assessment method [4]
0
0
The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change.
Query!
Timepoint [4]
0
0
Day 1 (Baseline) and Week 52
Query!
Secondary outcome [5]
0
0
Percent Change in Triglycerides From Baseline to Week 52
Query!
Assessment method [5]
0
0
The table below shows the mean percent change in triglycerides from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change.
Query!
Timepoint [5]
0
0
Day 1 (Baseline) and Week 52
Query!
Secondary outcome [6]
0
0
Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52
Query!
Assessment method [6]
0
0
The table below shows the mean percent change in HDL-C from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change.
Query!
Timepoint [6]
0
0
Day 1 (Baseline) and Week 52
Query!
Eligibility
Key inclusion criteria
* All patients must have a diagnosis of T2DM and be currently treated with metformin and sulphonylurea
* Patients in the study must have a HbA1c between >=7 and <=10.5% and a fasting plasma glucose (FPG) <300 mg/dL (16.7 mmol/L)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
* or a severe hypoglycemic episode within 6 months before screening
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/07/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2012
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
756
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Idaho
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kansas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Louisiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Massachusetts
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Michigan
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Nebraska
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Jersey
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Mexico
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New York
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Pennsylvania
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
South Carolina
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Tennessee
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Texas
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Virginia
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Washington
Query!
Country [27]
0
0
Austria
Query!
State/province [27]
0
0
Salzburg
Query!
Country [28]
0
0
Austria
Query!
State/province [28]
0
0
Wien
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Hedersem (Aalst)
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Tremelo
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
Belem
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Brasilia
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
Fortaleza
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
Goiânia
Query!
Country [35]
0
0
Brazil
Query!
State/province [35]
0
0
Marília
Query!
Country [36]
0
0
Brazil
Query!
State/province [36]
0
0
Passo Fundo
Query!
Country [37]
0
0
Brazil
Query!
State/province [37]
0
0
Porto Alegre
Query!
Country [38]
0
0
Brazil
Query!
State/province [38]
0
0
Rio De Janeiro
Query!
Country [39]
0
0
Brazil
Query!
State/province [39]
0
0
Sao Paulo
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Alberta
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
British Columbia
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Nova Scotia
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
Ontario
Query!
Country [44]
0
0
Canada
Query!
State/province [44]
0
0
Prince Edward Island
Query!
Country [45]
0
0
Canada
Query!
State/province [45]
0
0
Quebec
Query!
Country [46]
0
0
Canada
Query!
State/province [46]
0
0
Pointe-Claire
Query!
Country [47]
0
0
Canada
Query!
State/province [47]
0
0
Toronto
Query!
Country [48]
0
0
Denmark
Query!
State/province [48]
0
0
Aalborg
Query!
Country [49]
0
0
Denmark
Query!
State/province [49]
0
0
Ballerup
Query!
Country [50]
0
0
Denmark
Query!
State/province [50]
0
0
Gentofte
Query!
Country [51]
0
0
Denmark
Query!
State/province [51]
0
0
Vejle
Query!
Country [52]
0
0
Denmark
Query!
State/province [52]
0
0
Vipperoed
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Bondy Cedex
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Dijon
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Marseille
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Nantes
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Narbonne Cedex
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Paris
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Pessac
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
St Etienne
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Berlin
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Dresden
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Eisenach
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Großheirath
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Meißen
Query!
Country [66]
0
0
India
Query!
State/province [66]
0
0
Bangalore
Query!
Country [67]
0
0
India
Query!
State/province [67]
0
0
Coimbatore
Query!
Country [68]
0
0
India
Query!
State/province [68]
0
0
Hyderabad
Query!
Country [69]
0
0
India
Query!
State/province [69]
0
0
Jaipur
Query!
Country [70]
0
0
India
Query!
State/province [70]
0
0
Nagpur
Query!
Country [71]
0
0
India
Query!
State/province [71]
0
0
Nashik
Query!
Country [72]
0
0
India
Query!
State/province [72]
0
0
Pune
Query!
Country [73]
0
0
Israel
Query!
State/province [73]
0
0
Beer Sheba
Query!
Country [74]
0
0
Israel
Query!
State/province [74]
0
0
Jerusalem
Query!
Country [75]
0
0
Israel
Query!
State/province [75]
0
0
Kfar Saba
Query!
Country [76]
0
0
Israel
Query!
State/province [76]
0
0
Nazareth
Query!
Country [77]
0
0
Israel
Query!
State/province [77]
0
0
Rishon Lezion
Query!
Country [78]
0
0
Israel
Query!
State/province [78]
0
0
Tel-Aviv
Query!
Country [79]
0
0
Korea, Republic of
Query!
State/province [79]
0
0
Busan
Query!
Country [80]
0
0
Korea, Republic of
Query!
State/province [80]
0
0
Daegu
Query!
Country [81]
0
0
Korea, Republic of
Query!
State/province [81]
0
0
Jeonju-Si
Query!
Country [82]
0
0
Korea, Republic of
Query!
State/province [82]
0
0
Seongnam
Query!
Country [83]
0
0
Korea, Republic of
Query!
State/province [83]
0
0
Seoul
Query!
Country [84]
0
0
Malaysia
Query!
State/province [84]
0
0
Ipoh
Query!
Country [85]
0
0
Malaysia
Query!
State/province [85]
0
0
Johor Bahru
Query!
Country [86]
0
0
Malaysia
Query!
State/province [86]
0
0
Kelantan
Query!
Country [87]
0
0
Malaysia
Query!
State/province [87]
0
0
Selangor
Query!
Country [88]
0
0
Netherlands
Query!
State/province [88]
0
0
Breda
Query!
Country [89]
0
0
Netherlands
Query!
State/province [89]
0
0
Eindhoven
Query!
Country [90]
0
0
Netherlands
Query!
State/province [90]
0
0
Groningen
Query!
Country [91]
0
0
Netherlands
Query!
State/province [91]
0
0
Leiderdorp
Query!
Country [92]
0
0
Netherlands
Query!
State/province [92]
0
0
Rotterdam
Query!
Country [93]
0
0
Netherlands
Query!
State/province [93]
0
0
Velp Gld
Query!
Country [94]
0
0
Netherlands
Query!
State/province [94]
0
0
Zoetermeer
Query!
Country [95]
0
0
New Zealand
Query!
State/province [95]
0
0
Christchurch
Query!
Country [96]
0
0
New Zealand
Query!
State/province [96]
0
0
Dunedin
Query!
Country [97]
0
0
New Zealand
Query!
State/province [97]
0
0
Rotorua
Query!
Country [98]
0
0
New Zealand
Query!
State/province [98]
0
0
Tauranga
Query!
Country [99]
0
0
New Zealand
Query!
State/province [99]
0
0
Wellington
Query!
Country [100]
0
0
Poland
Query!
State/province [100]
0
0
Bialystok
Query!
Country [101]
0
0
Poland
Query!
State/province [101]
0
0
Chrzanow
Query!
Country [102]
0
0
Poland
Query!
State/province [102]
0
0
Gdansk
Query!
Country [103]
0
0
Poland
Query!
State/province [103]
0
0
Kamieniec Zabkowicki
Query!
Country [104]
0
0
Poland
Query!
State/province [104]
0
0
Krakow
Query!
Country [105]
0
0
Poland
Query!
State/province [105]
0
0
Lublin
Query!
Country [106]
0
0
Poland
Query!
State/province [106]
0
0
Sobotka
Query!
Country [107]
0
0
Poland
Query!
State/province [107]
0
0
Sopot
Query!
Country [108]
0
0
Poland
Query!
State/province [108]
0
0
Torun
Query!
Country [109]
0
0
Poland
Query!
State/province [109]
0
0
Wroclaw
Query!
Country [110]
0
0
Poland
Query!
State/province [110]
0
0
Zabrze
Query!
Country [111]
0
0
Singapore
Query!
State/province [111]
0
0
Singapore
Query!
Country [112]
0
0
Ukraine
Query!
State/province [112]
0
0
Dnepropetrovsk
Query!
Country [113]
0
0
Ukraine
Query!
State/province [113]
0
0
Ivano Frankivsk
Query!
Country [114]
0
0
Ukraine
Query!
State/province [114]
0
0
Kharkov
Query!
Country [115]
0
0
Ukraine
Query!
State/province [115]
0
0
Kiev
Query!
Country [116]
0
0
Ukraine
Query!
State/province [116]
0
0
Odessa
Query!
Country [117]
0
0
Ukraine
Query!
State/province [117]
0
0
Poltava
Query!
Country [118]
0
0
Ukraine
Query!
State/province [118]
0
0
Sumy
Query!
Country [119]
0
0
Ukraine
Query!
State/province [119]
0
0
Ternopil
Query!
Country [120]
0
0
Ukraine
Query!
State/province [120]
0
0
Vinnitsa
Query!
Country [121]
0
0
Ukraine
Query!
State/province [121]
0
0
Zaporozhye
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01137812
Query!
Trial related presentations / publications
Cai J, Delahanty LM, Akapame S, Slee A, Traina S. Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials. Patient. 2018 Jun;11(3):341-352. doi: 10.1007/s40271-017-0290-4. Qiu R, Balis D, Xie J, Davies MJ, Desai M, Meininger G. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Curr Med Res Opin. 2017 Mar;33(3):553-562. doi: 10.1080/03007995.2016.1271780. Epub 2017 Jan 4. Schernthaner G, Lavalle-Gonzalez FJ, Davidson JA, Jodon H, Vijapurkar U, Qiu R, Canovatchel W. Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes. Postgrad Med. 2016 Nov;128(8):725-730. doi: 10.1080/00325481.2016.1210988. Epub 2016 Jul 26. Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016 Jan;101(1):157-66. doi: 10.1210/jc.2015-3167. Epub 2015 Nov 18. Lavalle-Gonzalez FJ, Eliaschewitz FG, Cerdas S, Chacon Mdel P, Tong C, Alba M. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Curr Med Res Opin. 2016;32(3):427-39. doi: 10.1185/03007995.2015.1121865. Epub 2016 Jan 14. Bailey RA, Vijapurkar U, Meininger G, Rupnow MF, Blonde L. Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials. Clin Ther. 2015 May 1;37(5):1045-54. doi: 10.1016/j.clinthera.2015.02.020. Epub 2015 Mar 18. Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia. 2014 May;57(5):891-901. doi: 10.1007/s00125-014-3196-x. Epub 2014 Mar 1. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, Kawaguchi M, Canovatchel W, Meininger G. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013 Sep;36(9):2508-15. doi: 10.2337/dc12-2491. Epub 2013 Apr 5. Erratum In: Diabetes Care. 2013 Dec;36(12):4172.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen Research & Development, LLC C. Clinical Trial
Query!
Address
0
0
Janssen Research & Development, LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01137812
Download to PDF